Mounjaro clinical data and weight-loss effects: the latest evidence explained

  • Published:
  • Updated:
  • Written by the Hiro Clinic Medical Weight Loss editorial team
  • 48 min read
Medically reviewed by Dr. Hiroko Oka Reviewed byDr. Hiroko OkaCertified Member, Japanese Society of Internal Medicine Editorial policy
Mounjaro clinical data and weight-loss effects: the latest evidence explained

Key points firstShort on time? Just read this

  • Mounjaro is a drug whose effects on weight loss and blood sugar have been confirmed in several large clinical trials
  • In data from large clinical trials, serious side effects of Mounjaro were uncommon; most were digestive symptoms early in treatment
  • Mounjaro is considered especially likely to help people with obesity at a BMI of 30 or higher, or a BMI of 27 or higher with related health conditions

What you will learn in this article

  • How Mounjaro (tirzepatide) works, and clinical trial data on weight loss and blood sugar improvement
  • Results of the major clinical trials SURMOUNT-1, SURMOUNT-2, SURPASS-1 and SURPASS-2
  • How Mounjaro’s effects differ from other GLP-1 receptor agonists
  • Precautions for use and tips for continuing treatment safely

Introduction

Mounjaro is a drug whose effects on weight loss and blood sugar have been confirmed in several large clinical trials. In recent years, obesity has come to be seen not just as a matter of weight gain but as a serious health problem that raises the risk of lifestyle-related diseases such as type 2 diabetes, high blood pressure, dyslipidemia and cardiovascular disease. As a result, drug therapy is becoming more important as a weight-management strategy. Among these drugs, Mounjaro, a GIP/GLP-1 receptor agonist, is attracting attention for weight-loss treatment in people with obesity. This article explains Mounjaro’s clinical data, its actual weight-loss effects, how it compares with existing GLP-1 receptor agonists, and precautions for use.

1. What is Mounjaro?

Mounjaro is an injectable drug with a unique feature: it acts on two hormones, GLP-1 and GIP, at the same time. Mounjaro is classified as an injectable drug that acts on the receptors for both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). GLP-1 is an incretin hormone released from the intestine; when blood sugar rises, it promotes insulin secretion and suppresses glucagon secretion. In addition, Mounjaro acts on the parts of the central nervous system involved in appetite, and is characterized by suppressing appetite and leading to a natural reduction in how much you eat.

Features

  • Easy to continue with a once-weekly subcutaneous injection
  • Appetite suppression through its action on the central nervous system
  • Can improve blood sugar and reduce weight at the same time

2. How Mounjaro works

Mounjaro works through three pathways — the pancreas, the liver and the brain — to improve blood sugar and reduce weight at the same time. Mounjaro has the following three main actions.

  1. Action on pancreatic beta cells
    • Promotes insulin secretion when blood sugar rises
  2. Action on pancreatic alpha cells
    • Suppresses glucagon secretion and reduces glucose production in the liver
  3. Action on the appetite center
    • Acts on areas of the brain involved in appetite regulation to suppress appetite
    • As a result, leads to a natural reduction in calorie intake and weight loss

These three actions work together, making it possible to improve blood sugar and reduce weight at the same time.

3. Mounjaro clinical trial data

The effects of Mounjaro (generic name: tirzepatide) are supported by two large series of clinical trials, the SURMOUNT trials and the SURPASS trials. All results presented here come from clinical trials in which Mounjaro itself (tirzepatide) was given. Even among GLP-1-type drugs, these results should be kept separate from trial results for other drugs such as semaglutide.

3.1 Weight-loss effects (SURMOUNT trials)

In clinical trials in people with obesity, Mounjaro showed significant weight loss. Representative trial results are shown below.

  • SURMOUNT-1 trial (Jastreboff AM et al., 2022)
    • Participants: adults with obesity or overweight without diabetes (BMI of 30 or higher, or BMI of 27 or higher with an obesity-related condition)
    • Treatment: Mounjaro once-weekly subcutaneous injection (5 mg / 10 mg / 15 mg)
    • Results: average weight loss over 72 weeks was 15.0% in the 5 mg group, 19.5% in the 10 mg group and 20.9% in the 15 mg group
    • Average weight loss in the placebo group was only 3.1%
  • SURMOUNT-2 trial (Garvey WT et al., 2023)
    • Participants: people with type 2 diabetes and obesity or overweight
    • Results: average weight loss over 72 weeks was 13.4% in the 10 mg group and 15.7% in the 15 mg group (3.3% in the placebo group)

3.2 Blood sugar improvement (SURPASS trials)

In trials in people with type 2 diabetes, Mounjaro showed not only weight loss but also improvements in blood sugar.

  • SURPASS-1 trial (Rosenstock J et al., 2021)
    • Compared with placebo in people with type 2 diabetes not taking other diabetes drugs
    • HbA1c fell by up to 2.07% over 40 weeks (it rose by 0.04% in the placebo group)
  • SURPASS-2 trial (Frías JP et al., 2021)
    • Compared Mounjaro with semaglutide 1 mg (a conventional GLP-1 drug)
    • Over 40 weeks, HbA1c fell by 2.01% in the Mounjaro 5 mg group, 2.24% in the 10 mg group and 2.30% in the 15 mg group, exceeding the 1.86% reduction in the semaglutide group

Taken together, several clinical trials have shown that in people with type 2 diabetes and obesity, weight loss and blood sugar control can be achieved together. The risk of hypoglycemia is considered relatively low when Mounjaro is used alone because its action depends on blood sugar levels, but note that the risk increases when it is combined with insulin or sulfonylurea (SU) drugs.

Why not start with an online consultation to see whether Mounjaro suits you?

Book a consultation now *This is self-pay treatment. Effects and side effects vary from person to person.

4. Comparison with other GLP-1 receptor agonists

Because Mounjaro acts on both GIP and GLP-1, its mechanism differs from existing drugs that act only on GLP-1. Compared with existing GLP-1 receptor agonists (such as liraglutide and semaglutide), Mounjaro has the following features.

DrugDosing frequencyAverage weight loss in clinical trialsFeatures
Mounjaro (tirzepatide)Once weeklyAbout 15–21% (SURMOUNT-1, highest dose)Dual GIP/GLP-1 action
Liraglutide (Saxenda)Once dailyAbout 5–10% (SCALE trial)GLP-1 action only
Semaglutide (Wegovy)Once weeklyAround 15% (STEP 1 trial)GLP-1 action only; strong weight-loss effect at high doses
  • With the added GIP action, Mounjaro showed greater HbA1c reduction and weight loss than semaglutide in the SURPASS-2 trial
  • Because the trials differ in participant background (such as whether participants had diabetes and how severe it was), be careful about trial design differences when comparing the numbers directly

5. Actual weight-loss effects and clinical use

Clinical use of Mounjaro is considered in three situations: patients with a high BMI, patients with diabetes, and patients for whom conventional drugs were not effective enough. In clinical practice, Mounjaro is used effectively in situations such as the following.

  1. Weight management for patients with a high BMI
    • Appetite suppression allows weight loss without strain
  2. Patients with type 2 diabetes whose blood sugar control is inadequate
    • Improves blood sugar and reduces weight at the same time
  3. Patients with obesity for whom conventional drugs were not effective enough
    • A new weight-loss approach through dual GIP/GLP-1 action

Note that in Japan, Mounjaro is approved only for the treatment of type 2 diabetes and has not been approved as a treatment for obesity disease. Using Mounjaro for weight loss is off-label use, and many clinics, including Hiro Clinic, offer it as self-pay treatment (paid entirely by the patient).

6. Precautions for use

While Mounjaro is highly effective, care is needed regarding digestive symptoms and certain medical histories. Check the following points before starting treatment.

  1. Digestive symptoms
    • Nausea, constipation, diarrhea and similar symptoms have been reported early in treatment; these can be reduced by adjusting the dose
  2. Risk of pancreatitis
    • Pancreatitis can rarely develop, so seek medical care if you have severe abdominal pain or persistent digestive symptoms
  3. Not for use during pregnancy or breastfeeding
    • Cannot be used because safety has not been established
  4. Patients with reduced kidney function
    • Dose adjustment and monitoring are needed

7. Safety of Mounjaro

In data from large clinical trials, serious side effects of Mounjaro were uncommon; most were digestive symptoms early in treatment.

  • Across the SURMOUNT and SURPASS trials, serious side effects were rare
  • Early digestive symptoms often ease with continued treatment or by adjusting the pace of dose escalation
  • Follow-up studies on long-term safety are still ongoing

Not sure if it suits you? Start with a consultation.

A doctor decides whether you can use it and which dose is appropriate, based on your consultation and questionnaire.

No consultation fee (first & follow-up visits)Online consultation available

8. Summary so far

Mounjaro is a GIP/GLP-1 receptor agonist shown in two clinical trial series, SURMOUNT and SURPASS, to both reduce weight and improve blood sugar. Its distinguishing feature is that it acts on two hormones, GIP and GLP-1, and because it is given once weekly it is easy to continue, which makes it highly useful in practice.

  • In the SURMOUNT-1 trial, average weight loss over 72 weeks was 15–21% (3.1% in the placebo group)
  • In the SURPASS-2 trial, HbA1c fell by up to 2.30% in people with type 2 diabetes
  • Some trial results suggest greater weight loss than with other GLP-1 receptor agonists

As part of an obesity treatment strategy, combining it with lifestyle improvements allows safer and more effective weight management.

9. How Mounjaro is used in clinical practice

In clinical practice, treatment usually starts at a low dose and is increased step by step, together with lifestyle guidance. Mounjaro is used in clinical practice with the following guidance and management.

  1. Starting treatment and dose escalation
    • Start at a low dose and gradually increase to the standard dose while keeping digestive symptoms under control
    • Adjust the dose for each individual patient
  2. Combining with lifestyle measures
    • Combining appropriate calorie management and exercise maximizes the weight-loss effect
    • Support for behavior change in cooperation with dietitians and doctors is recommended
  3. Regular follow-up
    • Regularly check weight, blood pressure, blood sugar, kidney function and other measures
    • Adjust the treatment plan according to side effects and changes in health
  4. Importance of patient education
    • Explain how to inject and how to deal with side effects in advance
    • Weight loss appears gradually, so encourage patients to continue without rushing for short-term results

10. Mounjaro and cardiovascular risk management

Sub-analyses of the SURPASS trials have reported a tendency for blood pressure and lipid measures to improve with Mounjaro use. Recent studies have reported that GIP/GLP-1 receptor agonists may also contribute to improving cardiovascular risk factors. A sub-analysis of the SURPASS-2 trial reported a tendency toward improved blood pressure and lipid abnormalities in people with type 2 diabetes using Mounjaro; however, as of the time of writing, results from large outcome trials directly testing whether it reduces cardiovascular events themselves are still limited.

Doctor

11. Key points in selecting patients for Mounjaro

Mounjaro is considered especially likely to help people with obesity at a BMI of 30 or higher, or a BMI of 27 or higher with related health conditions. Patients for whom Mounjaro is particularly expected to be effective are as follows.

  • Patients with obesity and a BMI ≥30 kg/m²
  • Patients with a BMI ≥27 kg/m² and conditions such as diabetes or high blood pressure
  • Patients who did not achieve enough weight loss with conventional lifestyle changes or drug therapy
  • Patients who need weight management through appetite suppression

On the other hand, use should be avoided during pregnancy or breastfeeding and in patients with severe pancreatic disease.

12. Side effects and safety management

Mounjaro is generally a safe drug, but four points need particular attention: digestive symptoms, pancreatitis, hypoglycemia and kidney function.

  1. Digestive symptoms
    • Nausea, constipation, diarrhea
    • Usually occur early in treatment and ease with dose adjustment or over time
  2. Pancreatitis
    • Seek medical care if you have severe abdominal pain or persistent digestive symptoms
  3. Hypoglycemia
    • Rare when used alone, but take care when combined with insulin or sulfonylurea (SU) drugs
  4. Kidney impairment
    • Use with caution in patients with existing kidney disease

With regular blood tests and clinical monitoring, treatment can be safe and effective.

13. Future outlook

Mounjaro’s role is expanding from a diabetes drug to an option for treating obesity, but approval as a treatment for obesity disease in Japan remains an open question. GIP/GLP-1 receptor agonists, including Mounjaro, are shifting from being simply diabetes drugs to being a central option in obesity treatment. In particular, the strong weight-loss effect from the added GIP action has made possible results that conventional diet methods could not achieve.

There are also hopes for its use in improving cardiovascular risk factors and preventing lifestyle-related diseases, and Mounjaro’s role in future obesity treatment algorithms is expected to become more important. However, as of the time of writing, it is not clear when its indication in Japan will be expanded to include obesity disease.

With the clinical data in mind, why not talk to a doctor about whether this treatment is right for you?

Book a consultation now *This is self-pay treatment. Effects and side effects vary from person to person.

About self-pay treatment and off-label use

Self-pay treatment
Medical weight loss is self-pay treatment (paid in full by the patient) and is not covered by public health insurance.
Off-label use
Using medicines for weight management or weight loss may be off-label use, outside the indications approved in Japan.
Relief System for Adverse Drug Reactions
With off-label use, health damage such as a serious side effect may not be covered by Japan’s Relief System for Adverse Drug Reactions.
Individual differences and the doctor’s judgment
Effects and side effects vary from person to person. A doctor decides after a consultation whether you can use a medicine and which medicine and dose are appropriate. Please tell us in advance about any symptoms, chronic conditions or medicines you are taking.

FAQ

Here are answers to questions about Mounjaro’s clinical data that we often hear in consultations.

Q1. Does the “20.9% weight loss” in the SURMOUNT-1 trial apply to everyone?
A

No. This figure is the average among clinical trial participants who used Mounjaro 15 mg for 72 weeks. Results vary depending on age, sex, constitution and lifestyle, and the same result is not guaranteed.

Q2. Which is more effective, Mounjaro or semaglutide?
A

In the SURPASS-2 trial, Mounjaro showed greater HbA1c reduction and weight loss than semaglutide 1 mg in people with type 2 diabetes. However, results from trials with different participants and conditions cannot simply be compared, and which drug is more suitable depends on your constitution and treatment goals.

Q3. Is Mounjaro covered by health insurance in Japan as an obesity treatment?
A

No. In Japan, Mounjaro is approved only for the treatment of type 2 diabetes and has not been approved as a treatment for obesity disease. Use for weight loss is off-label use and is self-pay treatment not covered by health insurance (paid entirely by the patient).

Q4. Are the effects in clinical trial data the same as at an actual clinic?
A

Clinical trials show results in participants managed under set conditions, whereas in actual practice each person’s constitution, other medical conditions and lifestyle differ. Treat clinical trial data only as a rough guide, and check your progress with your doctor to see the actual effect.

Q5. What is the difference between the SURMOUNT and SURPASS trials?
A

The SURMOUNT trials are a series that mainly tested weight-loss effects in people with obesity or overweight, while the SURPASS trials are a series that mainly tested blood sugar improvement in people with type 2 diabetes. Because the participants and outcome measures differ, which data to refer to depends on your purpose.

Summary

Mounjaro is an obesity treatment option with the following features.

  • Strong weight-loss effects have been confirmed in the SURMOUNT-1 and SURMOUNT-2 trials
  • The SURPASS-1 and SURPASS-2 trials show it can also improve blood sugar in people with type 2 diabetes
  • Some trial results suggest that its dual GIP/GLP-1 action produces greater weight loss than existing GLP-1-only drugs
  • Side effects such as digestive symptoms and the risk of pancreatitis need to be managed

Combined with lifestyle improvements, it can improve obesity safely and effectively and also help lower the risk of related conditions. In clinical practice, patient education, regular follow-up and appropriate patient selection are the keys to successful treatment.

References

All figures presented in this article are based on peer-reviewed papers on Mounjaro (tirzepatide).

  1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
  2. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.
  3. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398:143-155.
  4. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.

Medically reviewed by: Dr. Hiroko Oka (Chair, Fukubikai Medical Corporation / Certified Member, Japanese Society of Internal Medicine)

Who to contact if you have side effects | When to seek medical care

If you have any of the following symptoms, contact us rather than waiting to see what happens. GIP/GLP-1 receptor agonists, including Mounjaro, are known to cause side effects, mainly digestive symptoms. Most are mild, but serious ones occasionally occur.

SymptomPossible causeWhat to do
Ongoing nausea or vomitingDigestive symptoms; the most common side effectContact us if you remain unable to keep fluids down
Severe abdominal pain (pain that spreads to the back)Possible acute pancreatitisStop the injections immediately and seek medical care
Cold sweat, palpitations, strong hunger, feeling confused or drowsyHypoglycemiaTake sugar immediately and contact us
Skin rash, difficulty breathing, swelling of the face or throatAllergic reactionSeek medical care immediately

Contact: 0120-241-929 (9:00–18:00)
If your symptoms are severe outside these hours, go to your nearest emergency medical facility.

Direct phone numbers for each clinic are listed on the clinic information page.

References

The information about medicines in this article is based on the following official sources. For details on dosage, administration and side effects, always check the latest package insert.
Pharmaceuticals and Medical Devices Agency (PMDA), “Mounjaro Subcutaneous Injection Ateos: package insert” (Japanese)
PMDA, “Drug Guide for Patients: Mounjaro Subcutaneous Injection Ateos” (PDF, Japanese)
Ministry of Health, Labour and Welfare, “Prevention of lifestyle-related diseases” (Japanese)

Using Mounjaro for purposes other than obesity disease is self-pay treatment and is not covered by public health insurance. Effects and side effects vary from person to person.

Reviewing doctor: Hiroko Oka
Reviewing doctor

Hiroko OkaDirector, Hiro Clinic Kawaguchi (physician)

Japanese Society of Internal Medicine About our medical review and editorial policy

You may also like

Back to all articles

Ask our AI chat AI chat